Program Introduction

Stay at the forefront of epilepsy care with this essential CME activity led by experts from UCLA Neurology. Get concise updates on epilepsy classification, treatment gaps, and emerging therapies across all ages. Topics include syndrome-specific strategies, psychosocial factors, and real-world insights to enhance patient-centered care and clinical outcomes. 

Learning Objectives

After completing this educational activity, you should be able to: 

• Recognize current updates on the burden and classification of epilepsy and specific epilepsy subtypes and syndromes. 
• Discuss the latest developments in epilepsy pharmacotherapy and the need for improved management. 
• Evaluate psychosocial considerations in the management of epilepsy, including treatment-related considerations with use of complex pharmacotherapy regimens in special patient populations.  

Available Credit

• 1.0 AMA PRA Category 1 Credit™
• 1.0 Participation

This CME activity is eligible for credit only to those who complete a Manuscript Peer Review and obtain and Enrollment code. 

CME credit for physicians or CE participation credit for nonphysicians is awarded for reviews submitted in a timely manner and in recognition of the learning that takes place during a manuscript review.

To be awarded credit and receive a certificate for this activity, peer-review learners must have completed their peer review in a timely manner and have provided constructive criticism to the author and Editor. The peer reviewer must complete the following Evaluation form to claim credit.

You will be awarded 3.00 AMA PRA Category 1 Credit^TM for this activity. The ACCME allows up to 15.00 AMA PRA Category 1 Credit^TM for peer review to be claimed each year.

Learning Objective

We anticipate learners will make improvements in their ability to critically review research manuscripts, as well as incorporate new research findings into their own practice as appropriate. 

Available Credit

Program Introduction

This program brings together leading experts to explore advancements in the diagnosis and treatment of Alzheimer’s disease (AD). Presented by Marc E. Agronin, MD, R. Scott Turner, PhD, MD, and Susan Scanland, MSN, this program addresses key challenges and solutions in AD care. Topics include strategies for early detection and diagnosis through cognitive assessments, neuroimaging, and biomarker analysis; the role of novel and investigational disease-modifying therapies and the integration of therapeutic approaches, including FDA-approved treatments and nonpharmacologic interventions. The session emphasizes the importance of multidisciplinary management and shared decision-making with patients and caregivers to create comprehensive and effective care plans.

Learning Objectives

• Identify biomarkers in screening for Alzheimer’s disease and in continual assessment of symptoms
• Recognize the safety and efficacy of novel therapies that are approved as well as investigational therapies in late-stage development in Alzheimer’s disease
• Assess opportunities to screen for early-stage Alzheimer’s disease including various administration methods, cognitive assessments and imaging

Available Credit

• 1.0 AMA PRA Category 1 Credit™
• 1.0 Participation

Program Introduction

Join Leo Wang and Maya Hatch for an insightful journey into the world of Facioscapulohumeral Muscle Dystrophy (FSHD), covering its etiology, clinical presentations, and the complexities of assessing treatment outcomes in clinical trials. Key focuses include the innovative Reachable Workspace (RWS) metric for functional assessment, the impact of current clinical trials, and emerging therapeutic targets. Discussions will also highlight biomarker insights, disease mechanisms like DUX4 regulation, and future strategies for FSHD management. Don’t miss this opportunity to gain insights from experts shaping the future of FSHD research and care, along with perspective from a real-world patient living with FSHD.

Learning Objectives

• Evaluate the use of RWS as an outcome measure for FSHD clinical trials to measure disease progression, impact on ADLs, and effect of therapy
• Discuss the mechanism of FSHD disease that leads to challenges in DUX4 biomarker detection

Available Credit

• 1.00 AMA PRA Category 1 Credit^TM
• 1.00 Participation